Digital Twin in Pharma Manufacturing — CMC Implications of the Virtual Batch

Pharmaceutical companies are investing in digital twin technology for manufacturing process simulation — and most of them are discovering that the regulatory framework for using digital twin outputs in CMC submissions and process validation is considerably less defined than the technology vendors implied.

The gap between what digital twin platforms promise and what FDA will accept in a regulatory submission is not a minor technical footnote — it is a program-level risk. Companies that build their process characterization strategy around digital twin outputs, only to discover during submission review that the model validation documentation does not meet the evidentiary standard FDA expects, face a timeline consequence that cannot be recovered without generating new experimental data. The value of digital twin technology in pharmaceutical manufacturing is real, but it is contingent on understanding the regulatory frontier before the modeling work begins.

What a Digital Twin Is in a Pharmaceutical Manufacturing Context: Technical Definition and Scope

The term “digital twin” is used loosely across pharmaceutical manufacturing contexts, which is itself a regulatory problem. Operationally, there are three distinct categories of digital twin that a CMC practitioner must distinguish before any regulatory planning can begin. The first is a process simulation model — a mechanistic model of a unit operation such as granulation, lyophilization, or crystallization — validated against experimental data and used to map CPP-CQA relationships within a design space context as described under ICH Q8(R2). The second is a real-time process digital twin, in which the model runs in parallel with the physical process, updated by live sensor data, and used to inform or trigger process adjustment decisions during manufacturing. The third is a predictive maintenance digital twin, which simulates equipment performance trajectories to anticipate maintenance requirements before failure occurs.

These three categories are not interchangeable from a regulatory standpoint, and treating them as though they exist on a single compliance continuum is one of the most common strategic errors at organizations in the early stages of digital twin implementation. The first category — process simulation — can support process development data documented in CTD Module 3.2.P.2 if the model validation is formally documented with transparent mechanistic derivation and parameter estimation methodology. The third category — predictive maintenance — functions in an advisory role and does not require Computer Software Assurance validation under FDA’s 2022 CSA guidance. The second category — real-time process digital twin — sits at the most consequential regulatory threshold: if model output triggers a GMP decision, including process adjustment or batch disposition, it requires full CSA validation under the 2022 guidance.

ICH Q13 on Continuous Manufacturing provides relevant precedent for digital tools in process monitoring contexts, recognizing that computational models can support process understanding in continuous manufacturing settings — but Q13 also makes clear that the rigor of model qualification must be commensurate with the role the model plays in process control. That principle — scope of use determines validation burden — is the architectural logic that should govern every digital twin implementation decision in a GMP-regulated environment.

The CMC Implications of Digital Twin Technology: How It Changes Process Characterization and PV

Where process simulation digital twins offer the most immediate CMC value is in design space definition and process characterization — specifically, the ability to evaluate CPP-CQA relationships across a range of process conditions that would require extensive physical experimentation to characterize otherwise. Under ICH Q8(R2), in silico modeling is recognized as a tool for pharmaceutical development, and a mechanistic model validated against experimental data can support the scientific rationale for design space boundaries documented in 3.2.P.2. The regulatory requirement is not that the model be perfect, but that its performance be characterized: prediction error must be quantified, uncertainty bounds must be documented, and the parameter estimation methodology must be transparent enough that an FDA reviewer can evaluate the reliability of the model-generated data.

The failure mode at the submission stage is predictable and repeated: companies reference digital twin model outputs in their CMC submission to support design space or process validation claims without documenting the model validation itself. The FDA reviewer cannot assess what the model does, how its predictions were tested, or what the prediction error was under the conditions relevant to the commercial process. The submission is not self-contained, and a deficiency results. This is not a theoretical risk — it reflects the general deficiency pattern that emerges when modeling technology is adopted by development teams without parallel regulatory strategy input on what the model validation documentation must contain before that output can appear in a submission.

The scale transition problem compounds this. Process simulation models are frequently built using laboratory-scale data — data generated during early development where the unit operation parameters are well-characterized but the geometric and hydrodynamic conditions at commercial scale are substantially different. If the model is not validated against pilot- or commercial-scale experimental data, or if the scale-up validation is not documented as part of the model qualification package, then the model’s outputs cannot be used to support commercial batch CQA predictions in a process validation context. This is the mechanistic reason why digital twin investment made early in development, without a scale-up validation roadmap, often cannot generate CMC submission-ready outputs — the model’s evidentiary foundation does not extend to the scale at which it is being used.

The Regulatory Framework for Digital Twins: Where FDA and EMA Have Issued Guidance

FDA has not issued specific guidance on digital twin use in pharmaceutical manufacturing as of 2025. The nearest regulatory precedents are the Process Analytical Technology guidance from 2004, FDA’s Computer Software Assurance guidance issued in 2022, and the FDA Discussion Paper on AI/ML in Pharmaceutical Development from 2023. Each of these documents contributes a piece of the applicable framework, but none was written with digital twins specifically in mind, and none resolves the central regulatory question of what a validated digital twin model must look like when it is used to support process validation or CMC submission data.

The 2022 CSA guidance introduced a risk-based approach to computer software validation in GMP contexts, replacing the prior emphasis on comprehensive documentation with a framework that scales validation rigor to the impact of the software on product quality. For digital twins whose output influences GMP decisions — including real-time process adjustments, batch release recommendations, or process validation conclusions — the CSA guidance is the operative framework, and “risk-based” does not mean “reduced documentation.” It means that the documentation must be proportional to and justified by the software’s actual role in quality-affecting decisions. A real-time process digital twin that triggers a process parameter adjustment in a biologics manufacturing suite is not a low-risk application under any reasonable CSA analysis.

The appropriate regulatory engagement pathway for novel digital twin applications — particularly those intended for use in process validation or commercial batch disposition — is FDA’s Emerging Technology Program. The program exists precisely for this category of innovation: manufacturing technologies and computational tools whose regulatory pathway is not fully defined by existing guidance and for which early FDA engagement can prevent costly submission deficiencies. Companies planning to use digital twin outputs in CMC regulatory submissions without prior FDA Emerging Technology Program engagement are, in practical terms, conducting an uncontrolled regulatory experiment on their own submission timeline.

Digital Twin Implementation in CMC: The Data Infrastructure Requirements and Regulatory Pathway

The XGene Pharmaceutical Digital Twin Regulatory Integration Framework provides a structured methodology for categorizing digital twin use cases, establishing model validation requirements, determining CSA scope, and building the regulatory documentation infrastructure before CMC submission — not after.

Step 1 — Use Case Categorization and Regulatory Burden Assignment. Classify each digital twin application as a development tool, a GMP control tool, or a maintenance advisory tool, because the regulatory burden — from no CSA requirement to full CSA validation — is entirely determined by whether model output influences any GMP decision or regulatory submission; this categorization must be completed before model development begins, not after deployment.

Step 2 — Model Validation Documentation Scoping. For any digital twin classified as a development or GMP control tool, define the required model validation package: documented mechanistic derivation, transparent parameter estimation methodology, quantified prediction error, uncertainty bounds, and experimental data validation at the scale of intended use — because an undocumented model produces inadmissible submission data regardless of how sophisticated the underlying modeling is.

Step 3 — CSA Scope Determination and Software Validation Planning. Apply the FDA 2022 Computer Software Assurance framework to determine the validation rigor required for each GMP-context digital twin, mapping each model output that triggers or informs a GMP action to a documented validation activity that establishes the software’s fitness for that specific function.

Step 4 — FDA Emerging Technology Program Engagement Roadmap. For digital twin applications intended to support process validation or commercial batch disposition, develop the engagement strategy for FDA’s Emerging Technology Program before the CMC submission is drafted — including the technical briefing package that defines the model’s role, the validation approach, and the proposed regulatory pathway — because pre-submission alignment eliminates the deficiency cycle that results from submitting model-generated data that FDA reviewers have no established framework to evaluate.

The output of this framework is a regulatory-ready digital twin implementation package that maps every model output to its regulatory use category, its validation documentation, and its CSA status — not a technology assessment, but a submission-ready evidence dossier.

Companies that proceed with digital twin implementation as a technology initiative rather than a regulatory strategy initiative will arrive at the CMC submission stage with model outputs they cannot use and a documentation gap that cannot be closed without repeating experiments they believed were already complete. The regulatory framework for digital twins in pharmaceutical manufacturing is being defined in real time, and the companies that engage FDA’s Emerging Technology Program early — before the model is built into their process validation strategy — are the ones that will establish the precedents that define this space. The cost of retroactive model validation, and the timeline consequence of a CMC deficiency built on unvalidatable computational outputs, is not recoverable in a commercial program timeline. The decision to invest in regulatory strategy before digital twin deployment is made once; the decision to defer it is paid for repeatedly.

For any digital twin model your organization uses or plans to use in pharmaceutical manufacturing — whether for process simulation, real-time monitoring, or predictive maintenance — determine whether the model output influences any GMP decision or regulatory submission, and assess whether that use requires CSA validation documentation under FDA’s 2022 Computer Software Assurance guidance.